Cholera vaccine live attenuated(Institute For International Vaccine Development Inc)(Cholera vaccine live attenuated(Institute For International Vaccine Development Inc))

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

Cholera vaccine live attenuated、CholeraGarde、Live attenuated oral cholera vaccine

+ [1]

靶点-

作用机制

免疫刺激剂

治疗领域

感染其他疾病

在研适应症

霍乱

非在研适应症

腹泻麻疹

原研机构

Institute For International Vaccine Development Inc

在研机构

Institute For International Vaccine Development Inc

非在研机构

AVANT Immunotherapeutics, Inc.Vaccine Technologies, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的临床试验

NCT00741637 / Completed临床2期IIT

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Single Dose Regimen of Live Attenuated Oral Cholera Vaccine (Choleragarde®) in HIV-Seropositive Adults in Thailand

The purpose of this study is to assess the safety and immunogenicity of Peru-15 (CholeraGarde®) vaccine in HIV seropositive adult population of Bangkok Thailand

开始日期2010-07-01

申办/合作机构

International Vaccine Institute

[+2]

NCT00624975 / Terminated临床2期IIT

A Multi-site, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Trehalose-reformulated Peru-15 (Choleragarde)Vaccine Given Simultaneously With Measles Vaccine in Healthy Indian and Bangladeshi Infants

The purpose of this study is to confirm the safety and immunogenicity of Peru-15 vaccine in infants when given simultaneously with measles vaccine.

开始日期2008-11-01

申办/合作机构

International Vaccine Institute

[+4]

100 项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的临床结果

登录后查看更多信息

100 项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的转化医学

登录后查看更多信息

100 项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的专利（医药）

登录后查看更多信息

27

项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的文献（医药）

2021-04-07·The American Journal of Tropical Medicine and Hygiene4区 · 医学

Home Administration of CVD 103-HgR: A Live Attenuated Oral Cholera Vaccine

4区 · 医学

Article

作者: Niedan, Volker ; Shabram, Paul ; Delbuono, Michael ; Chew, Lawrence ; Duffin, R. Paul ; Schwarz, Pascal ; Patel, Amish A. ; Johnstone, James

ABSTRACTVaccination is a well-established means for prevention and spread of disease in people traveling abroad. Although vaccines to diseases such as cholera are recommended by world health agencies, they are seldom required even when traveling to endemic regions. Consequences of noncompliance can affect traveler’s health and spread diseases to new regions, as occurred in Haiti in 2010 when United Nations peacekeepers from Nepal, where a cholera outbreak was underway, introduced the disease to the region. Steps to increase vaccine recommendation compliance should therefore be an integral part of vaccine development. PXVX0200 contains Center for Vaccine Development 103-HgR live, attenuated recombinant Vibrio cholerae vaccine strain, and is indicated for single-dose immunization against the bacteria that causes cholera. It is supplied as one buffer and one active component packet to be mixed into water and ingested. Administration instructions are designed to be “user friendly” with flexibility for self-administration, thus promoting compliance. Studies to support self-administration were conducted to cover stability of the vaccine outside of normal storage conditions, potency in case of misadministration, and disposal procedures to minimize environmental impact. The principal findings showed that the stability of vaccine was maintained under conditions allowing for transport times and temperature conditions as well as when misadministration errors were made. Finally, the vaccine was effectively neutralized with hot water and soap to prevent bacterial environmental contamination in the event of an accidental spill. The conclusion is that PXVX0200 oral vaccine is stable, easy to formulate and dispose of, and is amenable to self-administration.

2020-11-19·Journal of Bacteriology3区 · 生物学

Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice

3区 · 生物学

Article

作者: Waldor, Matthew K. ; Fakoya, Bolutife ; Sit, Brandon

Oral cholera vaccines (OCVs) are being deployed to combat cholera, but current killed OCVs require multiple doses and show little efficacy in young children. Live OCVs have the potential to overcome these limitations, but small-animal models for testing OCVs have shortcomings. We used an antibiotic treatment protocol for conventional adult mice to study the effects of short-term colonization by a single dose of HaitiV, a live-OCV candidate. Vaccinated mice developed vibriocidal antibodies against V. cholerae and delivered pups that were resistant to cholera, whereas mice vaccinated with inactivated HaitiV did not. These findings demonstrate HaitiV’s immunogenicity and suggest that this antibiotic treatment protocol will be useful for evaluating the efficacy of live OCVs.

2020-01-02·Human Vaccines & Immunotherapeutics3区 · 医学

An overview of Vaxchora^TM, a live attenuated oral cholera vaccine

3区 · 医学

Article

作者: Kim, Jerome H. ; Saluja, Tarun ; Mogasale, Vijayalaxmi V. ; Excler, Jean-Louis ; Mogasale, Vittal

Cholera remains a public health threat among the least privileged populations and regions affected by conflicts and natural disasters. Together with Water, Sanitation and Hygiene practices, use of oral cholera vaccines (OCVs) is a key tool to prevent cholera. Bivalent whole-cell killed OCVs have been extensively used worldwide and found effective in protecting populations against cholera in endemic and outbreak settings. No cholera vaccine had been available for United States (US) travelers at risk for decades until 2016 when CVD 103-HgR (Vaxchora™), an oral live attenuated vaccine, was licensed by the US FDA. A single dose of Vaxchora™ protected US volunteers against experimental challenge 10 days and 3 months after vaccination. However, use of Vaxchora™ poses several challenges in resource poor settings as it requires reconstitution, is age-restricted to 18 to 64 years, has no data in populations endemic for cholera, and faces challenges related to cold chain and cost.

100 项与 Cholera vaccine live attenuated(Institute For International Vaccine Development Inc) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
霍乱	临床2期	-	Institute For International Vaccine Development Inc	-
腹泻	临床1期	印度	AVANT Immunotherapeutics, Inc.	2008-11-01
腹泻	临床1期	印度	Vaccine Technologies, Inc.	2008-11-01
腹泻	临床前	印度	AVANT Immunotherapeutics, Inc.	2008-11-01
腹泻	临床前	印度	Vaccine Technologies, Inc.	2008-11-01
腹泻	临床前	孟加拉国	AVANT Immunotherapeutics, Inc.	2008-11-01
麻疹	临床前	孟加拉国	Vaccine Technologies, Inc.	2008-11-01
腹泻	药物发现	孟加拉国	AVANT Immunotherapeutics, Inc.	2008-11-01
腹泻	药物发现	孟加拉国	Vaccine Technologies, Inc.	2008-11-01
腹泻	药物发现	孟加拉国	Vaccine Technologies, Inc.	2008-11-01